Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Dec 1, 2018 in Hypertension | 0 comments

In a nutshell

This study investigated if a low-dose, triple-combination pill (LD-TCP) could reduce blood pressure (BP) in patients with persistent hypertension (PHT).

They found that LD-TCP increased the chance of reaching BP target after 6 months. 

Some background

Hypertension or high blood pressure is a common condition. Managing blood pressure (BP) levels is important. This helps to prevent cardiovascular events (CVE) such as heart disease and stroke. Some patients have persistent hypertension (PHT). PHT is difficult to treat as patients do not respond to medication. It can be challenging to manage BP levels in patients with PHT.

Some studies suggest that combining different types of medications to regulate BP may be useful in PHT patients. One option is using a low dose of three BP-lowering medications. This is called low dose, triple combination pill (LD-TCP) therapy. This is a new approach to managing BP levels. It is unclear if LD-TCP is safe and effective in managing BP in patients with PHT.

Methods & findings

This study included 700 adults with PHT. 349 patients received LD-TCP and 351 patients received standard treatment. The LD-TCP was made up of telmisartan (20 mg), amlodipine (2.5 mg) and chlorthalidone (12.5 mg). Treatment was received once daily. Blood pressure was measured at 6, 12 weeks and 6 months. BP targets were less than 140/90 mmHg or 130/80 mmHg for patients with diabetes or kidney disease.

At 6 weeks, 68% of LD-TCP patients reached their BP target compared to 44% of standard care patients. At 12 weeks, 73% of LD-TCP patients reached their BP target compared to 47% of standard care patients. At 6 months, 70% of LD-TCP patients reached their BP target compared to 55% of standard care patients. The number of side events was similar in LD-TCP and standard care groups (38% vs. 35%)

The bottom line

The authors concluded that LD-TCP increased the chance of reaching BP target after 6 months compared to standard treatments in patients with persistent hypertension.

The fine print

It is unclear if LD-TCP can reduce the risk of CVE. More investigation is needed.

What’s next?

If you have any concerns regarding hypertension please consult with your physician. 

Published By :

Annals of internal medicine

Date :

Nov 20, 2018

Original Title :

In persistent hypertension, low-dose triple-pill therapy increased the likelihood of achieving target BP at 6 mo.

click here to get personalized updates